Neogen’s second quarter saw a negative market reaction following results that reflected ongoing challenges in the company’s primary end markets. Management highlighted continued pressure on food producers due to prolonged inflation, leading to lower production volumes and a subdued environment for the Food Safety segment. CEO John Adent described the quarter as impacted by both external market softness and internal execution hurdles, particularly noting inefficiencies in sample collection production and elevated inventory write-offs. The segment’s pathogen detection and biosecurity products performed well, but these gains were offset by broader volume declines and operational costs.

Is now the time to buy NEOG? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Neogen’s Q2 Earnings Call

• Subhalaxmi T. Nambi (Guggenheim): Asked about the prudence built into guidance amid the CEO transition. CFO David Naemura replied that the approach remains business as usual, with no extraordinary assumptions for the new CEO.
• Subhalaxmi T. Nambi (Guggenheim): Inquired about the $10 million tariff headwind and how much of that is accounted for in next year’s outlook. Naemura confirmed the full amount is included in guidance.
• Brandon Vazquez (William Blair): Questioned whether the macro environment is worsening and how food safety market growth is factored into guidance. Naemura acknowledged sequential softening and growth assumptions in line with the low single digits.
• Jon Petersen (Piper Sandler): Sought clarity on expected differences in management style between incoming CEO Mike and outgoing CEO John Adent. Naemura noted that Mike is expected to take a back-to-basics approach, but detailed priorities will be shared in future quarters.
• Thomas DeBourcy (Nephron Research): Asked about market share gains in pathogen testing and unmet needs addressed by new launches. CEO John Adent highlighted investments in MDS platform assays and new products targeting Listeria and Salmonella as key drivers.

Catalysts in Upcoming Quarters

Looking forward, our analyst team will monitor (1) the pace and efficiency of the Petrifilm facility transition and its impact on margins, (2) progress in resolving production inefficiencies and inventory management, and (3) the company’s ability to leverage regulatory changes and new product introductions in pathogen detection to drive revenue growth. Updates on the genomics business divestiture and CEO transition will also be key signposts.

Neogen currently trades at $5.16, down from $5.43 just before the earnings. In the wake of this quarter, is it a buy or sell? The answer lies in our full research report (it’s free).

Our Favorite Stocks Right Now

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.